Results 241 to 250 of about 763,557 (307)

Editorial: Genetic and immunological insights in solid tumors: comprehensive approaches to treatment. [PDF]

Front Genet
Zhao Y, Ding C, Liu ZJ, Wang J, Zhou L.
europepmc   +1 more source

Spatiotemporal Sequential Delivery of Chidamide Regulates Macrophage Reprogramming in Lymphoma Microenvironment Through HDACs‐STAT3 Pathway

Advanced Science, EarlyView.
Our study identifies the HDACs‐STAT3 axis as key regulator for M2 macrophage accumulation in DLBCL. We developed Chid@M2pep‐EVs/TP, a pH‐responsive drug delivery system for M2 macrophage specific chidamide administration. By coupling M2‐targeted chidamide with EVs‐mediated delivery, this system reprograms M2 to M1 via HDAC inhibition and STAT3 ...
Bo Dai, Shuo Wang, Xiaotong Peng, Kunpeng Wu, Mengyao Wu, Zhaoning Lu, Haoshu Zhong, Xiaohan Qian, Shuiyi Tan, Hui Yang, Tanlezi Sun, Jing Wang, Jie Zhang, Hua Jiang, Yin Tong, Tong Chen   +15 more
wiley   +1 more source

Diagnostic and Therapeutic Applications of Exosomes in Lung Cancer. [PDF]

Cells
Moholkar DN, Kandimalla R, Wallen M, Yaddanapudi K, Gupta R, Aqil F.   +5 more
europepmc   +1 more source

IL‐3 Modulates Microglia Polarization and Attenuates Neuroinflammation in Traumatic Brain Injury

Advanced Science, EarlyView.
IL‐3 recruits PRDX1 through IL‐3R to modulate the inflammatory response of microglia via the KEAP1‐NRF2‐HO‐1/NF‐κB pathway to attenuate neuroinflammation in traumatic brain injury. ABSTRACT Microglia play a crucial role in the progression of neuroinflammation following traumatic brain injury (TBI). Interleukin‐3 (IL‐3), a significant regulatory factor,
Nana Huang, Qingchen Zhang, Yanrui Chen, Dapeng Yu, Ronghan Liu, Jianning Kang, Xiang Fang, Ying Zhang, Hong Bian, Yanxin Zhao, Yongcheng Yin, Ce Zhang, Yanfei Jia, Qingfa Chen, Yuepeng Fang, Shang Li, Fang Li, Zhengxin Jin, Bin Ning   +18 more
wiley   +1 more source

Clonorchis sinensis and cholangiocarcinoma: molecular mechanisms and biomarker advances. [PDF]

Parasite
Huang C, Wu Y, Wu A, Huang L, Fang S, Xu C, Liu T, Li Y, Li X.   +8 more
europepmc   +1 more source

PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC

Advanced Science, EarlyView.
CD4+ tissue‐resident memory T cells (TRMs) in non‐small cell lung cancer recruit conventional type 1 dendritic cells via XCL1‐XCR1 signaling, orchestrating antitumor immunity. The costimulatory molecule JAML is essential for this process. PD‐1 blockade restores JAML expression and cDC1 mobilization, while JAML agonists synergize with anti‐PD‐1 therapy,
Zheyu Shao, Qinyuan Liu, Zhongwei Xin, Zhiyao Zhou, Mingjie Lin, Di Chen, Zhixing Hao, Yongyuan Chen, Wenxuan Wu, Shuyang Zhang, Xiaoke Chen, Xia Xu, Jinfan Li, Wei Lin, Yuhao Lu, Dang Wu, Pin Wu   +16 more
wiley   +1 more source

Precision immunotherapy for breast cancer: from biomarkers to clinical practice. [PDF]

Cancer Biol Med
Mei J, Yang K, Zhang X, Huang X, Yin Y.
europepmc   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

Advanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin, Linlin Li, Dan Sun, Jiaguo Li, Tao Liu, Jun Guo, Wenfeng Xu, Weimin Zhu, Yi Liu, Boyang Sun, Jia Zhong, Lijie Rong, Qijun Qian, Chenqi Xu, Jie Wang   +23 more
wiley   +1 more source

Translational advances in gastric cancer: integrating biomarkers, novel therapies, and microenvironment remodeling in 2025. [PDF]

Transl Cancer Res
Feng X, Shi T, Wei J.
europepmc   +1 more source